Richard Eisenstadt
2016 - Neos Therapeutics
In 2016, Richard Eisenstadt earned a total compensation of $677.7K as Chief Financial Officer at Neos Therapeutics, a 46% decrease compared to previous year.
Compensation breakdown
| Bonus | $29,291 |
|---|---|
| Option Awards | $302,410 |
| Salary | $333,600 |
| Other | $12,380 |
| Total | $677,681 |
Eisenstadt received $333.6K in salary, accounting for 49% of the total pay in 2016.
Eisenstadt also received $29.3K in bonus, $302.4K in option awards and $12.4K in other compensation.
Rankings
In 2016, Richard Eisenstadt's compensation ranked 10,025th out of 14,075 executives tracked by ExecPay. In other words, Eisenstadt earned more than 28.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,025 out of 14,075 | 29th |
Division Manufacturing | 3,870 out of 5,489 | 30th |
Major group Chemicals And Allied Products | 1,360 out of 1,895 | 28th |
Industry group Drugs | 1,087 out of 1,538 | 29th |
Industry Pharmaceutical Preparations | 853 out of 1,176 | 28th |
Source: SEC filing on April 28, 2017.
Eisenstadt's colleagues
We found three more compensation records of executives who worked with Richard Eisenstadt at Neos Therapeutics in 2016.
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019